Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist ... for non-alcoholic steatohepatitis (NASH), a much larger population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback